Search Result

Results for "

BCL6 degradation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bcl-2 Family (5) BCL6 (13) Aquaporin (1) Btk (1) Caspase (1) CD20 (1) CDK (1) IKZF Family (2) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (3) Molecular Glues (5) PARP (1) PROTAC Linkers (1) PROTACs (9) Reference Standards (1)
By Research Areas:	Cancer (23) Inflammation/Immunology (3)

Targets Recommended: BCL6 Bcl-2 Family

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-158105

ARV-393 1 Publications Verification	PROTACs BCL6	Cancer
ARV-393 is a potent and orally active *BCL6* PROTAC degrader. ARV-393 induces ubiquitination of BCL6 and its subsequent degradation by the proteasome. ARV-393 has the potential for the research of advanced non-hodgkin lymphoma .

HY-108705

BI-3802 3 Publications Verification	Molecular Glues Bcl-2 Family	Cancer
BI-3802, a chemical probe, is a highly potent *BCL6* degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC₅₀ of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .

HY-172736

BMS-986458	PROTACs BCL6 CD20	Cancer
BMS-986458 is a highly selective, orally active cereblon-based *BCL6* PROTAC degrader and antitumor agent. BMS-986458 selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6, thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20. BMS-986458 modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of BMS-986458 with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. BMS-986458 induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma .

HY-146185

CCT373566	Molecular Glues Bcl-2 Family	Cancer
CCT373566 is a potent and orally active molecular glue degrader of transcriptional repressor BCL6, with an IC₅₀ of 2.2 nM. CCT373566 shows strong antiproliferative efficacy in vitro and reduction in tumor growth in vivo .

HY-122829

BCL6 PROTAC 1	PROTACs BCL6	Cancer
BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) PROTAC. BCL6 PROTAC 1 inhibits BCL6 cell reporter with an IC₅₀ value of 8.8 µM. BCL6 PROTAC 1 significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6 PROTAC 1 can be used in tumor related research .

HY-178803

PROTAC BCL6 Degrader-2	PROTACs BCL6	Cancer
PROTAC BCL6 Degrader-2 (Compound A19) is an orally active, selective *BCL6* PROTAC degrader (DC₅₀s: 34 pM in OCI-LY1 cells and 0.45 nM in HEK293T cells). PROTAC BCL6 Degrader-2 promotes the ubiquitination and degradation of BCL6. PROTAC BCL6 Degrader-2 exhibits anticancer activity against BCL6-dependent diffuse large B-cell lymphoma (Pink: BCL6 ligand (HY-178804); Blue: E3 ligase ligand (HY-W087383); E3 ligase ligand + linker (HY-W998306)) .

HY-178777

BCL6-760	PROTACs BCL6	Cancer
BCL6-760 is an orally active BCL-6 PROTAC degrader with an EC₅₀ of 0.8 nM. BCL6-760 only degrades BCL6 and has no effect on other CRBN substrates. BCL6-760 demonstrates significant efficacy in the orthotopic xenograft mouse model of OCI-LY-1 tumors. BCL6-760 can be used in the research of diffuse Large B-cell Lymphoma (DLBCL) (Pink: BCL-6 ligand (HY-179317); Blue: CRBN ligand (HY-179305); Black: Linker) .

HY-177755

BCL6-IN-10	Molecular Glues BCL6	Cancer
BCL6-IN-10 (Compound 6) is a selective partially degradable molecular glue inhibitor that targets the BTB domain of *BCL6* with an IC₅₀ of 4 nM. BCL6-IN-10 shows anti-proliferative effect in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6-IN-10 can be used for the research of cancer .

HY-177756

BCL6-IN-11	BCL6	Cancer
BCL6-IN-11 (Compound 8) is an efficient inhibitor that induces partial degradation of *BCL6* with its IC₅₀ value for inhibiting the interaction between BCL6 and its co-inhibitory proteins (such as NCOR1) of 6 nM. BCL6-IN-11 can induce approximately 52% degradation of BCL6 after being treated with 5 μM concentration for 90 minutes, and thus is also classified as a partial degrader. BCL6-IN-11 can be used for the study of lymphoma .

HY-178804

BCL6 ligand-5	Ligands for Target Protein for PROTAC BCL6	Cancer
BCL6 ligand-5 (Compound 37) is a *BCL6* ligand. BCL6 ligand-5 can be used as a ligand for target protein for PROTAC to develop and design degraders for PROTAC BCL6, such as PROTAC BCL6 Degrader-2 (HY-178803). BCL6 ligand-5 can also be used in tumor research .

HY-179075

PROTAC BCL6/IKZF1/3 Degrader-1	PROTACs BCL6 IKZF Family	Cancer
PROTAC BCL6/IKZF1/3 Degrader-1 is a selective and orally active *BCL6* and IKZF1/3 PROTAC degrader. PROTAC BCL6/IKZF1/3 Degrader-1 exhibits superior antiproliferative effects in various germinal center B-cell-like (GCB) and activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) cell lines. PROTAC BCL6/IKZF1/3 Degrader-1 can be used for the research of cancer, such as lymphoma . (Structure Note: Pink: BCL6/IKZF1/3 ligand (HY-179064); Blue: CRBN ligand (HY-41547); Black: linker (HY-42427); CRBN ligand-Linker: (HY-179066))

HY-179305

CBM-4077	Ligands for E3 Ligase	Cancer
CBM-4077 is a PROTAC E3 ligand that can be used for synthesis of PROTACs, such as BCL6-760 (HY-178777). BCL6-760 is a potent BCL6 PROTAC degrader with anti-tumor activity .

HY-179077

PROTAC BTK/IKZF1/3 Degrader-1	PROTACs Btk IKZF Family	Cancer
PROTAC BTK/IKZF1/3 Degrader-1 is a selective and orally active *BCL6* and IKZF1/3 PROTAC degrader. PROTAC BTK/IKZF1/3 Degrader-1 exhibits antitumor activity. PROTAC BTK/IKZF1/3 Degrader-1 can be used for the research of cancer, such as lymphoma . (Structure Note: Pink: BCL6/IKZF1/3 ligand (HY-179076); Blue: CRBN ligand (HY-41547))

HY-178683

ALV-05-077-01	Others	Cancer
ALV-05-077-01 is a BLC6/BLC6B degrader. ALV-05-077-01 depletes endogenous *BCL6* levels in SuDHL4 cells (high BCL6 expression) and *BCL6B* levels in KYO1 cells (high BCL6B expression). ALV-05-077-01 can be used for the study of hematological malignancies .

HY-178700

ALV-05-151-02	Others	Cancer
ALV-05-151-02 is a BLC6/BLC6B degrader. ALV-05-151-02 depletes endogenous BCL6 levels in SuDHL4 cells (high BCL6 expression) and BCL6B levels in KYO1 cells (high BCL6B expression). ALV-05-151-02 can be used for the study of hematological malignancies .

HY-179317

BCL6 ligand-8	Ligands for Target Protein for PROTAC BCL6	Cancer
BCL6 ligand-8 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as BCL6-760 (HY-178777). BCL6-760 is a potent BCL6 PROTAC degrader with anti-tumor activity .

HY-186067

PROTAC BCL6 Degrader-3	PROTACs BCL6	Inflammation/Immunology Cancer
PROTAC BCL6 Degrader-3 (compound 92) is a BCL6 PROTAC degrader. PROTAC BCL6 Degrader-3 can be used for the study of cancer or an autoimmune disease .

HY-146184

CCT373567	Molecular Glues Bcl-2 Family	Cancer
CCT373567 is a potent molecular glue degrader of transcriptional repressor BCL6, with an IC₅₀ of 2.9 nM. CCT373567 exhibits antiproliferative activity .

HY-186068

BCL6 ligand-9	BCL6 Ligands for Target Protein for PROTAC	Inflammation/Immunology Cancer
BCL6 ligand-9, a *BCL6* ligand, is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). BCL6 ligand-9 can be used for the synthesis of PROTAC BCL6 Degrader-3 (HY-186067) .

HY-181084

PROTAC BCL6/GSPT1 Degrader-1	PROTACs BCL6 Aquaporin PARP Caspase CDK	Cancer
PROTAC BCL6/GSPT1 Degrader-1 is a dual-target PROTAC degrader that targets *BCL6* and GSPT1. PROTAC BCL6/GSPT1 Degrader-1 inhibits cell proliferation, promotes DNA damage, and induces cell cycle arrest and apoptosis in diffuse large B-cell lymphoma. PROTAC BCL6/GSPT1 Degrader-1 can be used for research on tumors such as lymphoma .

HY-108705R

BI-3802 (Standard)	Molecular Glues Reference Standards Bcl-2 Family	Cancer
BI-3802 (Standard) is the analytical standard of BI-3802 (HY-108705). This product is intended for research and analytical applications. BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC₅₀ of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .

HY-182449

CCT365386	Bcl-2 Family	Cancer
CCT365386 is a *BCL6* inhibitor. CCT365386 serves as an optimized lead compound for cell-active *BCL6* degraders (including CCT369260 (HY-129188)). CCT365386 can be used in the research of B-cell lymphoma .

HY-W267161

(3R,4R)-3-Methyl-4-piperidinol	PROTAC Linkers	Inflammation/Immunology Cancer
(3R,4R)-3-Methyl-4-piperidinol is a PROTAC linker. (3R,4R)-3-Methyl-4-piperidinol can be used for the synthesis of PROTAC BCL6 Degrader-3 (HY-186067) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

BCL6 degradation

Inhibitors & Agonists